Role of Humoral Immunity in Host Defense Against HIV

We describe recent studies designed to improve the production, quality, and cross-reactivity of these antibodies

Linda L. Baum


Scholarcy highlights

  • The initial HIV vaccine trials were designed to stimulate the production of neutralizing antibodies against HIV envelope glycoproteins
  • Antibodies are a key component in host defense and in vaccines against HIV
  • Other antibodies interact with viral epitopes that are expressed on the surface of infected cells and target those cells for destruction by Fc receptor-bearing natural killer cells, monocytes, and neutrophils
  • The kind of activity that an antibody has is dependent upon two things: fine specificity and heavy chain class
  • The goal with vaccines is to stimulate the production of these antibodies so that when a pathogen is encountered, these antibodies are already present and able to block infection with cell-free virus or infected cells
  • Baum incorporate immunogens that will stimulate the production of as many protective specificities and functions of HIV antibodies as possible as well as cell-mediated immunity

Need more features? Save interactive summary cards to your Scholarcy Library.